Skip to main
SRPT

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics (SRPT) Analyst Ratings

Based on 24 analyst ratings
Hold
Strong Buy 13%
Buy 21%
Hold 50%
Sell 4%
Strong Sell 13%

Bulls say

Sarepta Therapeutics is expected to experience long-term success due to its focused approach on rare genetic diseases, diverse portfolio of approved treatments for neuromuscular disorders, and ongoing investments in research and development for future therapeutics. While the company carries a significant amount of debt, its strong cash position and continued commercial success of its current products justify its current valuation. However, potential risks such as uncertainties around FDA approvals and increasing competition in the market could impact the company's future performance.

Bears say

Sarepta Therapeutics is facing challenges in proving the efficacy of its treatments, as it has increasingly relied on external controls and non-randomized comparisons to showcase their benefits. Furthermore, the company's guide range for 2026 suggests a decline in revenues, and there are concerns about their ability to gain payer adoption and generate demand for their products. The recent shift towards heavier commercial execution also raises questions about the sustainability of their current trajectory. Overall, the financial and data metrics suggest a concerning outlook for Sarepta Therapeutics' stock.

Sarepta Therapeutics (SRPT) has been analyzed by 24 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 4% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sarepta Therapeutics (SRPT) Forecast

Analysts have given Sarepta Therapeutics (SRPT) a Hold based on their latest research and market trends.

According to 24 analysts, Sarepta Therapeutics (SRPT) has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sarepta Therapeutics (SRPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.